

Patent Docket P1134R2C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Avi J. Ashkenazi et al.

Serial No.: 10/688,132

Filed: October 17, 2003

For: DCR3 POLYPEPTIDE, A TNFR

HOMOLOG

Group Art Unit: to be assigned

Examiner: to be assigned

Confirmation No: 2023

CUSTOMER NO: 09157

CERTIFICATE OF EXPRESS MAILING

EXPRESS MAIL LABEL NO .: EV 384 509 805 US

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450".

Necember 22, 2006

Diane L. Marschang

TRANSMITTAL LETTER

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- 1. Supplemental Information Disclosure Statement;
- 2. Form PTO-1449 with <u>6</u> References;
- Return postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: December 22, 2006

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e Application of

Avi J. Ashkenazi et al.

Serial No.: 10/688,132

Filed: October 17, 2003

For: DCR3 POLYPEPTIDE, A TNFR

HOMOLOG

Group Art Unit: to be assigned

Examiner: to be assigned

Confirmation No: 2023

CUSTOMER NO: 09157

CERTIFICATE OF EXPRESS MAILING EXPRESS MAIL LABEL NO.: EV 384 509 805 US

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450".

December 22, 2006

Diane L. Marschang

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

Serial No.: 10/688,132

Filing Date: October 17, 2003

Page 2

[X] 37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[] 37 CFR §1.97(d)

• after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filling of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filling of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [X] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449. Copies of the items listed on the PTO-1449 form are supplied herewith, except for United States patent(s) and United States patent application publication(s) and other documents that are marked with an asterisk (*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR §1.98(a)(2)(ii)]. See Final Rule 1287 OG (October 12, 2004). Other documents cited with an asterisk have not been supplied because they were previously cited by or submitted to the Office

Serial No.: 10/688,132

Filing Date: October 17, 2003

Page 3

in prior application Serial No. 10/456,819, filed June 6, 2003 and benefit from the prior application is claimed in this application under 35 U.S.C §120. However, copies of any cited document will be provided in its entirety at the request of the Office.

A concise explanation of relevance of the items listed on PTO-1449 is:

- [X] not given
- [] given for each listed item
- given for only non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: Alcember 22, 2006

: Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416

	/	5
FORM PTO-1449	DEC 22	2006
LIST OF DISCLOSURES C	ITED THAPP	JOSEP T

U.S. Dept. of Commerce

Atty Docket No. P1134R2C4

Serial No. 10/688,132

		Patent and trademark Office	Applicant			
LIST OF DISCLOSURES CITED APPLICATION		Ashkenazi et al.				
(Use several sheets if necessary)			Filing Date	Group		
(000			17 Oct 2003			
		OTHER DISCLOSURES (Including Author, Title, Date, Po				
1		Hsu et al., "Attenuation of Th1 Response in Decoy Receptor 3 Tran 175:5135-5145 (2005)	nsgenic Mice" <u>Journa</u>	of Immunology		
2	2	Shen, "Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis" World Journal of Gastroenterology 11(38):5926-5930 (2005)				
~~~	3 ."	Suminoe et al., "mRNA expression of apoptosis-associated genes in infant acute lymphoblastic leukemia: low Fas expression is an indeptendent predictor for poor prognosis" <u>Leukemia</u> 18:365-368 ((online) 2003)				
. 4	1	Tsuji et al., "Endogenous Decoy Receptor 3 Blocks The Growth Inhibition Signals Mediated by Fas Ligand In Human Pancreatic Adenocarcinoma" Int. J. Cancer 106:17-25 (2003)				
.   5	5	Wu et al., "DcR3/TR6 Effectively Prevents Islet Primary Nonfuntion 52:2279-2286 (2003)				
6	6	Yang et al., "Soluble Decoy Receptor 3 Induces Angiogenesis by Ne Belonging to Tumor Necrosis Factor Superfamily and Exhibiting Ang $64:1122-1129$ (2004)	eutralization of TL1 <i>k</i> giostatic Action" <u>Car</u>	A, a Cytokine ncer Research		
		·				
	-					
		*		•		
·						
		·		*		
	-					
*						
Examiner	J	Date	e Considered			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation						